Free Trial

Maravai LifeSciences (MRVI) Stock Price, News & Analysis

Maravai LifeSciences logo
$3.09 +0.12 (+4.04%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$3.14 +0.05 (+1.75%)
As of 10/3/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Maravai LifeSciences Stock (NASDAQ:MRVI)

Advanced

Key Stats

Today's Range
$2.94
$3.30
50-Day Range
$2.03
$3.14
52-Week Range
$1.66
$8.53
Volume
1.83 million shs
Average Volume
1.32 million shs
Market Capitalization
$789.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.22
Consensus Rating
Hold

Company Overview

Maravai LifeSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

MRVI MarketRank™: 

Maravai LifeSciences scored higher than 71% of companies evaluated by MarketBeat, and ranked 298th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Maravai LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 3 buy ratings, 7 hold ratings, and 2 sell ratings.

  • Upside Potential

    Maravai LifeSciences has a consensus price target of $5.22, representing about 68.9% upside from its current price of $3.09.

  • Amount of Analyst Coverage

    Maravai LifeSciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Maravai LifeSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.24) to ($0.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Maravai LifeSciences is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Maravai LifeSciences is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Maravai LifeSciences has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Maravai LifeSciences' valuation and earnings.
  • Percentage of Shares Shorted

    13.67% of the float of Maravai LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Maravai LifeSciences has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in Maravai LifeSciences has recently increased by 3.60%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Maravai LifeSciences does not currently pay a dividend.

  • Dividend Growth

    Maravai LifeSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.67% of the float of Maravai LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Maravai LifeSciences has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in Maravai LifeSciences has recently increased by 3.60%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Maravai LifeSciences has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Maravai LifeSciences this week, compared to 9 articles on an average week.
  • Search Interest

    Only 1 people have searched for MRVI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.11% of the stock of Maravai LifeSciences is held by insiders.

  • Percentage Held by Institutions

    50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Maravai LifeSciences' insider trading history.
Receive MRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRVI Stock News Headlines

Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia’s Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet. But according to James Altucher, the real opportunity isn’t in Tesla or Nvidia. He’s uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia’s CEO has even called this company “essential” to their expansion.tc pixel
See More Headlines

MRVI Stock Analysis - Frequently Asked Questions

Maravai LifeSciences' stock was trading at $5.45 at the beginning of 2025. Since then, MRVI shares have decreased by 43.3% and is now trading at $3.09.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) issued its quarterly earnings results on Monday, May, 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. The company's quarterly revenue was down 26.9% on a year-over-year basis.
Read the conference call transcript
.

Maravai LifeSciences (MRVI) raised $1.3 billion in an IPO on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Maravai LifeSciences investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
5/12/2025
Today
10/05/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MRVI
CIK
1823239
Fax
N/A
Employees
610
Year Founded
2014

Price Target and Rating

High Price Target
$10.00
Low Price Target
$2.00
Potential Upside/Downside
+68.9%
Consensus Rating
Hold
Rating Score (0-4)
2.08
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$144.85 million
Net Margins
-90.03%
Pretax Margin
-159.73%
Return on Equity
-17.60%
Return on Assets
-9.30%

Debt

Debt-to-Equity Ratio
0.68
Current Ratio
5.16
Quick Ratio
4.49

Sales & Book Value

Annual Sales
$259.18 million
Price / Sales
3.04
Cash Flow
$0.62 per share
Price / Cash Flow
5.00
Book Value
$2.28 per share
Price / Book
1.36

Miscellaneous

Outstanding Shares
255,360,000
Free Float
249,974,000
Market Cap
$789.06 million
Optionable
Optionable
Beta
0.33

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:MRVI) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners